eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases

Copyright West LLC. Minimum 15 minutes delayed.

Recent News Releases
03/13/19
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
03/04/19
Eyenovia to Participate in Two Upcoming Investor Conferences
02/25/19
Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
Upcoming Events

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

295 Madison Ave., Suite 2400, New York, NY 10017     +1 (917) 289-1117

admin@eyenoviabio.com